非小细胞肺癌β-微管蛋白Ⅲ表达及其与含紫杉醇方案耐药的关系

刘萍; 王豪勋; 王海莉

doi:10.7619/jcmp.201303004

非小细胞肺癌β-微管蛋白Ⅲ表达及其与含紫杉醇方案耐药的关系

郑州大学第二附属医院肿瘤科,河南郑州,450014

基金项目: 中国高校医学期刊临床专项资金

详细信息

中图分类号: R734.2
计量
- 文章访问数: 211
- HTML全文浏览量: 38
- PDF下载量: 12
出版历程
- 发布日期: 2013-05-22

Relationship between β-tubulin Ⅲ expression and paclitaxel-containing regimen with drug resistance in non small-cell lung cancer

摘要

摘要: 目的探讨晚期非小细胞肺癌(NSCLC)组织中β-微管蛋白Ⅲ(β-tubulinⅢ)的表达及其与含紫杉醇方案耐药的关系.方法经病理学确诊为ⅢB～Ⅳ期的120例NSCLC患者随机分为2组,试验组60例给予紫杉醇/顺铂(TP)方案,对照组60例给予长春瑞滨/顺铂(NP)方案,2个周期后评价疗效.应用免疫组化法检测120例NSCLC组织中β-tubulinⅢ的表达并分析其与含紫杉醇方案耐药的关系.结果 NSCLC组织中β-tubulinⅢ表达水平与患者年龄、性别、分期及组织学类型无关.β-tubulinⅢ高表达与TP方案化疗耐药有关:TP方案化疗耐药者β-tubulinⅢ的高表达率为77.3％,明显高于敏感者的42.1％.β-tubulinⅢ高表达与NP方案化疗耐药无关.结论 β-tubulinⅢ在NSCLC组织中的表达水平与含紫杉醇方案耐药有关.
- 非小细胞肺癌 /
- β-微管蛋白Ⅲ /
- 紫杉醇 /
- 耐药

HTML全文

参考文献(14)

陈斯泽, 陈雪梅, 丁颖. 多西紫杉醇、卡培他滨和顺铂联合方案治疗转移性鼻咽癌的研究 [J]. 南方医科大学学报, 2011(7):1114.

陈斯泽, 陈雪梅, 丁颖. DC方案与PF方案化疗与同步放疗治疗中晚期食管鳞癌 [J]. 南方医科大学学报, 2011(4):727.

欧阳举, 杜先凤. 多西紫杉醇联合卡培他滨及亚叶酸钙治疗晚期胃癌87例临床分析 [J]. 海南医学院学报, 2011, (11):1500.doi: 46-1049/R.20110922.1711.006.

Kavallaris M. Microtubules and resistance to tubulin-binding agents [J]. Nature Reviews Cancer, 2010(4):194.

Jung M, Koo J S, Moon Y W. Overexpression of class Ⅲ beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy [J]. PLoS One, 2012(9):e45127.

Alli E, Yang J M, Ford J M. Revesal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells [J]. Molecular Pharmacology, 2007(5):1233.

Eng L, Ibrahim-zada I, Jarjanazi H. Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines [J]. BMC Med Genomics, 2011.18.

Hammond J W, Cai D, Verhey K I. Tubulin modifications and their cellular functions [J]. Current Opinion in Cell Biology, 2008(1):71.

Wade R H. Microtubules:an overview [J]. Methods in Molecular Medicine, 2007.1.

Wade R H. On and around microtubules:an overview [J]. Molecular Biotechnology, 2009(2):177.

Mozzetti S, Ferlini C, Concolino P. Class Ⅲ beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients [J]. Clinical Cancer Research, 2005(1):298.

Tommasi S, Mangia A, Lacalamita R. Cytoskeleton and paclitaxel sensitivity in breast cancer:the role of beta-tubulins [J]. International Journal of Cancer, 2007, (10):2078.

Sève P, Reiman T, Dumontet C. The role of beta Ⅲ β-tubulin in predicting chemoresistance in non-small cell lung cancer [J]. Lung Cancer, 2010(2):136.

Kang C H, Jang B G, Kim D W. The prognostic significance of ERCC1, BRCA1, XRCC1, and beta lll-tubulin expression in patients with non-small cell lung cancer treated by platinum-and taxane-based neoadjuvant chemotherapy and surgical resection [J]. Lung Cancer, 2010(3):478.

施引文献

资源附件(0)

计量

文章访问数: 211
HTML全文浏览量: 38
PDF下载量: 12
被引次数: 0

非小细胞肺癌β-微管蛋白Ⅲ表达及其与含紫杉醇方案耐药的关系

计量

出版历程

Relationship between β-tubulin Ⅲ expression and paclitaxel-containing regimen with drug resistance in non small-cell lung cancer

计量

出版历程

目录